Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 101 citing articles:

Long-term outcomes following CAR T cell therapy: what we know so far
Kathryn M. Cappell, James N. Kochenderfer
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 359-371
Open Access | Times Cited: 646
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels W.C.J. van de Donk, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 6, pp. e255-e269
Open Access | Times Cited: 92
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Mi Kwon, Gloria Iacoboni, Juan Luís Reguera, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 110-121
Open Access | Times Cited: 91
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 89
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
Kitsada Wudhikarn, Miguel‐Angel Perales
Bone Marrow Transplantation (2022) Vol. 57, Iss. 10, pp. 1477-1488
Open Access | Times Cited: 80
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
David M. Cordas dos Santos, Tobias Tix, Roni Shouval, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2667-2678
Open Access | Times Cited: 63
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
Jakob Passweg, Helen Baldomero, Fabio Ciceri, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 6, pp. 647-658
Open Access | Times Cited: 58
Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
Jakob Passweg, Helen Baldomero, Christian Chabannon, et al.
Bone Marrow Transplantation (2022) Vol. 57, Iss. 5, pp. 742-752
Open Access | Times Cited: 66
Systematic Review of Available CAR-T Cell Trials around the World
Luciana Rodrigues Carvalho Barros, Samuel Campanelli Freitas Couto, Daniela da Silva Santurio, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2667-2667
Open Access | Times Cited: 60
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
Eleftheria Kampouri, Carla S. Walti, Jordan Gauthier, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 4, pp. 305-320
Closed Access | Times Cited: 52
Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
Muhammad Bilal Abid, Micah Rubin, Nathan A. Ledeboer, et al.
Cancer Cell (2022) Vol. 40, Iss. 4, pp. 340-342
Open Access | Times Cited: 43
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Jean Lemoine, Emmanuel Bachy, Guillaume Cartron, et al.
Blood Advances (2023) Vol. 7, Iss. 21, pp. 6589-6598
Open Access | Times Cited: 41
CAR T cells for treating autoimmune diseases
Ulrich Blache, Sandy Tretbar, Ulrike Koehl, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e002907-e002907
Open Access | Times Cited: 39
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 30
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Gemma Reynolds, Victoria Hall, Benjamin W. Teh
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 28
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
Jessica S Little, Megha Tandon, Joseph Hong, et al.
Blood Advances (2023) Vol. 7, Iss. 18, pp. 5485-5495
Open Access | Times Cited: 24
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 5, pp. 685-685
Open Access | Times Cited: 10
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Jaap A. van Doesum, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood Advances (2023) Vol. 7, Iss. 11, pp. 2645-2655
Open Access | Times Cited: 21
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Per Ljungman, Gloria Tridello, José Luís Piñana, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Arielle Elkrief, Julie Wu, Chinmay Jani, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 303-330
Open Access | Times Cited: 35
Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy
Ester Márquez‐Algaba, Gloria Iacoboni, Berta Pernas, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 851.e1-851.e8
Open Access | Times Cited: 28
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
Chenghao Ge, Kelei Du, Mingjie Luo, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 810-821
Open Access | Times Cited: 25
SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
Kevin O. McNerney, Rebecca M. Richards, Paibel Aguayo‐Hiraldo, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 1, pp. e005957-e005957
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top